Filing summary
Identity discrepancy: The request identifies Viridian Therapeutics, Inc., but the supplied filing is for Miragen Therapeutics, Inc. (formerly Signal Genetics, Inc.). Confirm the filing belongs to the intended company before relying on this summary.
Business context and reporting period
This unaudited Form 10-Q covers the quarter and six months ended June 30, 2017; it was filed August 11, 2017. Miragen was a clinical-stage company developing microRNA-targeted therapeutics, with MRG-106 and MRG-201 in clinical trials and other candidates in preclinical development. The company reported no product sales.
In February 2017, the company completed a reverse merger with privately held Miragen, changed its name, and began trading as MGEN. The statements treat Private Miragen as the accounting acquirer; comparisons with 2016 therefore reflect a company and public-company cost base that changed substantially.
Financial performance and position
| Metric | Three months ended June 30 | Six months ended June 30 |
|---|---|---|
| Revenue | $0.718 million, down from $1.115 million | $1.180 million, down from $2.032 million |
| Research and development expense | $5.487 million, up from $3.355 million | $9.607 million, up from $6.821 million |
| General and administrative expense | $2.581 million, up from $1.210 million | $5.862 million, up from $2.202 million |
| Net loss | $7.312 million, versus $3.524 million | $14.292 million, versus $7.147 million |
| Net loss per share | $0.34, versus $5.88 | $0.87, versus $11.92 |
The much lower per-share loss reflects the larger post-merger share count, not improved profitability. Revenue consisted of collaboration and grant revenue; no product revenue was reported. Operating margins are not meaningful for this pre-revenue business, and the filing reports operating losses of $7.350 million for the quarter and $14.289 million for the six-month period.
At June 30, cash and cash equivalents were $46.335 million, compared with $22.104 million at December 31, 2016. Current assets were $49.350 million and current liabilities $6.630 million. Notes payable totaled $3.850 million, including $1.979 million current; the company repaid $1.0 million of principal during the first half.
Six-month operating cash use was $15.261 million, versus $8.633 million in 2016. Financing provided $38.361 million, principally from the $40.7 million February common-stock financing, net of issuance costs and debt payments. Cash increased by $24.231 million to $46.335 million.
Material changes and management outlook
- For the quarter, revenue fell by $0.4 million while R&D expense rose $2.1 million and G&A expense rose $1.4 million year over year. For the six months, revenue fell $0.852 million while R&D rose $2.786 million and G&A rose $3.660 million.
- Management attributed higher R&D costs mainly to outsourced manufacturing, increased research staffing and advancing clinical programs. Higher G&A reflected merger-related and public-company costs, professional services, and increased staffing.
- Management said available cash should fund operations in the normal course through the end of 2018. It also expected losses and R&D spending to rise for several years and stated that substantial additional capital would be needed; the company may pursue equity, debt, grants, or collaborations.
- The company had an ATM agreement allowing up to $50 million of common-stock sales, but had made no sales under it by June 30.
- Clinical update: MRG-106 had enrolled 24 MF subjects as of July 26, 2017; it was generally well tolerated, with one dose-limiting worsening of itching reported. The company expected to start dosing in additional blood-cancer indications in the second half of 2017 and intended to start an MF Phase 2 trial in 2018. The MRG-201 Phase 1 study was completed in Q2 2017; results were expected in the second half of 2017, with a Phase 2a keloid study intended for 2018.
- The May 2017 Servier amendment made microRNA-92 the primary collaboration target, extended the research term through September 2019, and included an approximately $0.5 million milestone payable upon a specified development goal or by November 15, 2017. The company retained U.S. and Japan rights to the target.
Risks, contingencies, and unusual items
- The company had an $81.4 million accumulated deficit, no approved products, and no product-sales revenue. Its ability to continue advancing programs depends on clinical results, financing access, and collaboration performance.
- Management highlighted the early-stage and unproven nature of microRNA therapeutics, uncertain trial outcomes, safety and delivery risks, manufacturing costs and supply dependence, and possible delays or failure to obtain regulatory approval.
- The February reverse merger and concurrent financing materially changed the company’s share count, capital structure, reporting costs, and comparability with prior periods. All redeemable preferred stock converted to common stock; none remained outstanding at June 30.
- Servier, university, and other licensing arrangements carry potential milestone, royalty, and sublicense-payment obligations. The filing also disclosed executive severance provisions, indemnification obligations, and a facility lease extending through August 2020.
- The company stated that it had no material commitments beyond those reflected or disclosed in the financial statements, no off-balance-sheet arrangements, and no legal proceedings reported in the filing. Management concluded disclosure controls were effective at a reasonable level of assurance.
Important facts for investors to verify
- Confirm the registrant identity: the source filing is Miragen Therapeutics, Inc., not Viridian Therapeutics, Inc.
- Review the reverse-merger accounting and the effect of the merger and concurrent financing on comparative results, share count, and per-share loss.
- Assess cash burn against the stated end-of-2018 runway and the need for additional capital; verify subsequent financing and ATM usage.
- Track MRG-106 and MRG-201 trial results, safety findings, enrollment, and whether the stated 2017–2018 development plans were achieved.
- Review the Servier amendment’s payment conditions, collaboration funding and obligations, and the company’s retained U.S. and Japan rights.
- Evaluate clinical-manufacturing feasibility, third-party supply dependence, license-related milestones and royalties, and the potential dilution or restrictions from future financing.